Eckert & Ziegler to Market Prostate Cancer Products in the U.S. / Shareholder Meeting Approves Dividend.

Berlin, 15.05.2002. Eckert & Ziegler AG, a manufacturer for radioactive implants for the treatment of prostate cancer, will start to directly market its products in the American market. For this purpose the company will utilize the customer base and sales force of ”Alliant Medical Technologies”, which filed for Chapter 7 relief on START_OF_TAGBREND_OF_TAGWednesday.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIn the United States approximately 60,000 patients each year chose radioactive implants for the treatment of prostate cancer. The method is significantly more economical than traditional surgical treatment and has lower side effects. Eckert & Ziegler is the leading European manufacturer of radioactive implants for the treatment of prostate cancer and had been barred previously from marketing directly in the U.S. by contractual restrictions. START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe shareholder meeting of Eckert & Ziegler Strahlen- und Medizintechnik today also approved a dividend of 0.45 EUR. Eckert & Ziegler has 3.25 mm shares and in 2001 reported earnings of about 3.2 mm EUR. START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe Board of DirectorsSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGFor further information please contact:START_OF_TAGBREND_OF_TAGKarolin RiehleSTART_OF_TAGBREND_OF_TAGInvestor RelationsSTART_OF_TAGBREND_OF_TAGEckert & Ziegler AGSTART_OF_TAGBREND_OF_TAGRobert-Rössle-Str. 10START_OF_TAGBREND_OF_TAGD - 13125 BerlinSTART_OF_TAGBREND_OF_TAGwww.ezag.comSTART_OF_TAGBREND_OF_TAGTel.: +49 (0) 30 / 94 10 84-138START_OF_TAGBREND_OF_TAGFax.:+49 (0) 30 / 94 10 84-112START_OF_TAGBREND_OF_TAG